Notice of Waiver of the Referral Requirement for TRICARE Prime Enrollees, Not Including Active Duty Service Members (ADSMs), So They May Receive COVID-19 Vaccines From Any TRICARE-Authorized Non-Network Provider Without Incurring Point-of-Service Charges Where Applicable, 10942-10943 [2021-03667]

Download as PDF 10942 Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices purpose of the proposed action is threefold: (1) Address the needs of fishing communities, consistent with NOAA’s mandate through the Saltonstall-Kennedy Act; (2) ensure NOAA continues to meet the requirements of the Saltonstall-Kennedy Act; and (3) assist NOAA in meeting its mission, ‘‘To understand and predict changes in climate, weather, oceans, and coasts, to share that knowledge and information with others, and to conserve and manage coastal and marine ecosystems and resources’’. The Proposed Action is needed to address the needs of fishing communities by building and maintaining sustainable fisheries, optimizing economic benefits, and increasing other opportunities to keep working waterfronts viable. Types of projects funded by the S–K Program include, but are not limited to, promotion and marketing; aquaculture; gear testing; bycatch reduction engineering; research and monitoring; stock assessments; data collection; socioeconomic research; climate change; and workshops and conferences. Alternatives NOAA is preliminarily preparing to analyze two program-level alternatives: (1) A No Action Alternative, and (2) the proposed action, which NOAA is referring to as the Promotion, Marketing, Research and Development Alternative. Under the No Action Alternative, the S– K Program would not fund projects that address the needs of fishing communities, optimize economic benefits by building and maintaining sustainable fisheries, and increase other opportunities to keep working waterfronts viable. Although the No Action Alternative would not meet the purpose and need, it serves as a baseline against which the impacts of the Promotion, Marketing, Research and Development Alternative will be compared and contrasted. Implementation of the Promotion, Marketing, Research and Development Alternative, will allow for funding actions through federal financial assistance for all possible types of projects that meet the needs of U.S. fishing communities, consistent with the scope of the S–K Program. This alternative would provide the S–K Program with flexibility in choosing priorities each year while also considering the funding environment. We invite public comments on the proposed scope of the alternatives and are particularly interested in comments regarding potential additional alternatives. VerDate Sep<11>2014 18:36 Feb 22, 2021 Jkt 253001 Scoping Process This notice initiates a public scoping period for the PEIS. Please review the information in this notice and additional information about the S–K Program, located on the NOAA S–K Program website (see the FOR FURTHER INFORMATION CONTACT section above). NOAA is particularly interested in receiving comments regarding biological, cultural, or ecological issues that the analysis should address. We also encourage comments that assist us in further delineating the proposed project, its potential to affect the human environment, means for avoiding, minimizing, or mitigating those effects, the preliminary range of alternatives, any additional reasonable alternatives that should be considered, and other issues of public concern. To promote informed decision-making, we especially encourage commenters to submit any scientific data, studies, or research that you feel is relevant to the analysis. To facilitate the public and agency involvement in the PEIS process, NOAA will hold three public-scoping meetings during the scoping period. The meetings will be virtual in format. The scoping meetings will solicit input from the public and interested public agencies regarding the scope of environmental impacts to be addressed in the draft PEIS. Three virtual public scoping meetings (in webinar format only) will be held in each of three regions, as follows: • Eastern and Gulf of Mexico Region (includes Atlantic States, Gulf of Mexico States, U.S. Virgin Islands, and Puerto Rico)—March 9, 2021 Æ 12:00 p.m.–3:00 p.m. Central Standard Time (CST) Æ 1:00 p.m.– 4:00 p.m. Eastern Standard Time (EST) • Western Region (includes Pacific States, Idaho, Alaska)—March 10, 2021 Æ 10:00 a.m.–1:00 p.m. Pacific Standard Time (PST) Æ 9:00 a.m.–12:00 p.m. Alaska Standard Time (AKST) • Western Pacific Region (includes Hawaii and Pacific Territories)— March 11, 2021, March 12, 2021 Æ March 11, 2021, 2:00 p.m.–5:00 p.m. Hawaii-Aleutian Standard Time (HST) Æ March 12, 2021, 10:00 a.m.–1:00 p.m. Chamorro Standard Time (CHST) Use the webinar link and dial-in information below to join one of the public scoping meetings: PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 Webinar Link: https:// kearnsandwest.webex.com/meet/ webexalias3 Access Code: 146 622 5582 Dial-in Information: 1–844–621–3956 (U.S. Toll Free) | +1–415–655–0001 (U.S. Toll) Participants are encouraged to download the Webex Meetings app ahead of the meetings, using this link: https://www.webex.com/ downloads.html. Then use the meeting link above to join a public scoping meeting at the appropriate time. You may also participate by phone toll-free by calling 1–844–621–3956, then entering the Access Code above when prompted. After the comment period closes, NOAA will review and consider all comments received during the comment period and any other relevant information when developing the draft PEIS. Upon completion of the draft PEIS, a document announcing its availability and an opportunity to comment will be published in the Federal Register. Authority: This PEIS will be prepared under the authority of, and in accordance with, the requirements of NEPA, implementing regulations published by the Council on Environmental Quality (40 CFR 1500–1508), other applicable regulations, and NOAA’s policies and procedures for compliance with those regulations. Dated: February 16, 2021. Daniel A. Namur, Director of the NMFS Financial Assistance Division, National Marine Fisheries Service. [FR Doc. 2021–03626 Filed 2–22–21; 8:45 am] BILLING CODE 3510–22–P DEPARTMENT OF DEFENSE Office of the Secretary Notice of Waiver of the Referral Requirement for TRICARE Prime Enrollees, Not Including Active Duty Service Members (ADSMs), So They May Receive COVID–19 Vaccines From Any TRICARE-Authorized Non-Network Provider Without Incurring Point-ofService Charges Where Applicable Office of the Secretary, Department of Defense (DoD). ACTION: Notice of waiver. AGENCY: This notice is to advise TRICARE Prime enrollees, not including ADSMs, of a waiver to the referral requirement so they may receive COVID–19 vaccines, a clinical preventive service, from any TRICARE authorized non-network provider SUMMARY: E:\FR\FM\23FEN1.SGM 23FEN1 Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices without incurring POS charges where applicable. This waiver is effective on December 13, 2020. ADDRESSES: Defense Health Agency (DHA), 16401 East Centretech Parkway, Aurora, CO 80011–9066. FOR FURTHER INFORMATION CONTACT: Valerie Palmer, Defense Health Agency, 303–676–3557, valerie.a.palmer3.civ@ mail.mil. DATES: In December 2019, an outbreak of respiratory disease caused by a novel coronavirus was detected in Wuhan City, Hubei Province, China. The virus has been named SARS–CoV–2 and the disease it causes has been named COVID–19. This virus has spread rapidly throughout the United States (U.S.) and around the world. On January 31, 2020, the Secretary of the Department of Health and Human Services, Alex Azar, declared a public health emergency pursuant to Section 319 of the Public Health Service Act for the entire U.S. to aid in the Nation’s health care community response to COVID–19, retroactive to January 27, 2020. On March 13, 2020, President Donald Trump declared that the COVID–19 outbreak in the U.S. constituted a national emergency, beginning March 1, 2020. Thus far, two vaccines have been approved by the Food and Drug Administration (FDA) for the prevention of COVID–19 in the U.S. On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) for the PfizerBioNTech COVID–19 vaccine (Pfizer, Inc.; Philadelphia, Pennsylvania). Vaccination with the Pfizer-BioNTech COVID–19 vaccine consists of two doses administered intramuscularly, three weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the PfizerBioNTech COVID–19 vaccine in persons aged 16 years and older for the prevention of COVID–19. The recommendation was published in an early release of the Morbidity and Mortality Weekly Report (MMWR) on December 13, 2020; thus, this vaccine may now be covered by TRICARE. On December 18, 2020, the FDA issued an EUA for the Moderna COVID– 19 (mRNA–1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts). Vaccination with the Moderna COVID– 19 vaccine consists of two doses administered intramuscularly, four weeks apart. On December 19, 2020, the ACIP issued an interim recommendation for use of the Moderna SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 18:36 Feb 22, 2021 Jkt 253001 COVID–19 vaccine in persons aged 18 years and older for the prevention of COVID–19. The recommendation was published in an early release of the MMWR on December 20, 2020; thus, this vaccine may also be covered by TRICARE. Except under very special circumstances, a beneficiary enrolled in TRICARE Prime is required to obtain a referral for care through a designated primary care manager (or other authorized care coordinator) prior to obtaining care under the TRICARE program, otherwise POS charges apply. The DHA believes the widespread need for COVID–19 vaccines and the fact that supply of these vaccines may be limited is a special circumstance necessitating the waiver of the referral requirement for TRICARE Prime enrollees so they may receive a COVID–19 vaccine, a clinical preventive service, from any TRICARE authorized non-network provider without incurring POS charges where applicable. This waiver will apply for the period of the U.S. President’s declaration of the COVID–19 national emergency. Dated: January 25, 2021. Aaron T. Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2021–03667 Filed 2–22–21; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF EDUCATION [Docket No.: ED–2021–SCC–0027] Agency Information Collection Activities; Comment Request; Reaffirmation Agreement Federal Student Aid, Department of Education (ED). ACTION: Notice. AGENCY: In accordance with the Paperwork Reduction Act of 1995, ED is proposing an extension without change of a currently approved collection. DATES: Interested persons are invited to submit comments on or before April 26, 2021. ADDRESSES: To access and review all the documents related to the information collection listed in this notice, please use http://www.regulations.gov by searching the Docket ID number ED– 2021–SCC–0027. Comments submitted in response to this notice should be submitted electronically through the Federal eRulemaking Portal at http:// www.regulations.gov by selecting the Docket ID number or via postal mail, commercial delivery, or hand delivery. If the regulations.gov site is not SUMMARY: PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 10943 available to the public for any reason, ED will temporarily accept comments at ICDocketMgr@ed.gov. Please include the docket ID number and the title of the information collection request when requesting documents or submitting comments. Please note that comments submitted by fax or email and those submitted after the comment period will not be accepted. Written requests for information or comments submitted by postal mail or delivery should be addressed to the PRA Coordinator of the Strategic Collections and Clearance Governance and Strategy Division, U.S. Department of Education, 400 Maryland Ave. SW, LBJ, Room 6W208D, Washington, DC 20202–8240. FOR FURTHER INFORMATION CONTACT: For specific questions related to collection activities, please contact Beth Grebeldinger, 202–377–4018. SUPPLEMENTARY INFORMATION: The Department of Education (ED), in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)), provides the general public and Federal agencies with an opportunity to comment on proposed, revised, and continuing collections of information. This helps the Department assess the impact of its information collection requirements and minimize the public’s reporting burden. It also helps the public understand the Department’s information collection requirements and provide the requested data in the desired format. ED is soliciting comments on the proposed information collection request (ICR) that is described below. The Department of Education is especially interested in public comment addressing the following issues: (1) Is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records. Title of Collection: Reaffirmation Agreement. OMB Control Number: 1845–0133. Type of Review: An extension without change of a currently approved collection. Respondents/Affected Public: Individuals and Households; Private Sector; State, Local, and Tribal Governments. E:\FR\FM\23FEN1.SGM 23FEN1

Agencies

[Federal Register Volume 86, Number 34 (Tuesday, February 23, 2021)]
[Notices]
[Pages 10942-10943]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03667]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Notice of Waiver of the Referral Requirement for TRICARE Prime 
Enrollees, Not Including Active Duty Service Members (ADSMs), So They 
May Receive COVID-19 Vaccines From Any TRICARE-Authorized Non-Network 
Provider Without Incurring Point-of-Service Charges Where Applicable

AGENCY: Office of the Secretary, Department of Defense (DoD).

ACTION: Notice of waiver.

-----------------------------------------------------------------------

SUMMARY: This notice is to advise TRICARE Prime enrollees, not 
including ADSMs, of a waiver to the referral requirement so they may 
receive COVID-19 vaccines, a clinical preventive service, from any 
TRICARE authorized non-network provider

[[Page 10943]]

without incurring POS charges where applicable.

DATES: This waiver is effective on December 13, 2020.

ADDRESSES: Defense Health Agency (DHA), 16401 East Centretech Parkway, 
Aurora, CO 80011-9066.

FOR FURTHER INFORMATION CONTACT: Valerie Palmer, Defense Health Agency, 
303-676-3557, [email protected].

SUPPLEMENTARY INFORMATION: In December 2019, an outbreak of respiratory 
disease caused by a novel coronavirus was detected in Wuhan City, Hubei 
Province, China. The virus has been named SARS-CoV-2 and the disease it 
causes has been named COVID-19. This virus has spread rapidly 
throughout the United States (U.S.) and around the world.
    On January 31, 2020, the Secretary of the Department of Health and 
Human Services, Alex Azar, declared a public health emergency pursuant 
to Section 319 of the Public Health Service Act for the entire U.S. to 
aid in the Nation's health care community response to COVID-19, 
retroactive to January 27, 2020. On March 13, 2020, President Donald 
Trump declared that the COVID-19 outbreak in the U.S. constituted a 
national emergency, beginning March 1, 2020.
    Thus far, two vaccines have been approved by the Food and Drug 
Administration (FDA) for the prevention of COVID-19 in the U.S. On 
December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) 
for the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc.; Philadelphia, 
Pennsylvania). Vaccination with the Pfizer-BioNTech COVID-19 vaccine 
consists of two doses administered intramuscularly, three weeks apart. 
On December 12, 2020, the Advisory Committee on Immunization Practices 
(ACIP) issued an interim recommendation for use of the Pfizer-BioNTech 
COVID-19 vaccine in persons aged 16 years and older for the prevention 
of COVID-19. The recommendation was published in an early release of 
the Morbidity and Mortality Weekly Report (MMWR) on December 13, 2020; 
thus, this vaccine may now be covered by TRICARE.
    On December 18, 2020, the FDA issued an EUA for the Moderna COVID-
19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts). 
Vaccination with the Moderna COVID-19 vaccine consists of two doses 
administered intramuscularly, four weeks apart. On December 19, 2020, 
the ACIP issued an interim recommendation for use of the Moderna COVID-
19 vaccine in persons aged 18 years and older for the prevention of 
COVID-19. The recommendation was published in an early release of the 
MMWR on December 20, 2020; thus, this vaccine may also be covered by 
TRICARE.
    Except under very special circumstances, a beneficiary enrolled in 
TRICARE Prime is required to obtain a referral for care through a 
designated primary care manager (or other authorized care coordinator) 
prior to obtaining care under the TRICARE program, otherwise POS 
charges apply. The DHA believes the widespread need for COVID-19 
vaccines and the fact that supply of these vaccines may be limited is a 
special circumstance necessitating the waiver of the referral 
requirement for TRICARE Prime enrollees so they may receive a COVID-19 
vaccine, a clinical preventive service, from any TRICARE authorized 
non-network provider without incurring POS charges where applicable. 
This waiver will apply for the period of the U.S. President's 
declaration of the COVID-19 national emergency.

    Dated: January 25, 2021.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2021-03667 Filed 2-22-21; 8:45 am]
BILLING CODE 5001-06-P